Molecular biomarkers and targets for Fuchs' endothelial corneal dystrophy and glaucoma
AssigneeBoard of Regents, The University of Texas System
InventorsVenkateswara Vinod Mootha, David R. Corey, Jiaxin Hu, Yongjun Chu
Life of this patent
Estimating the term…
Abstract
Molecular biomarkers relating to Fuchs' endothelial corneal dystrophy (FECD), glaucoma, and other degenerative ocular diseases are provided, as well as methods for using such biomarkers methods of treatment. These biomarkers may be used to monitor the progression of FECD, glaucoma, or other degenerative ocular diseases. Furthermore, these biomarkers may be used to monitor the treatment of FECD, glaucoma, or other degenerative ocular diseases.
Claims7
A method of monitoring treatment of Fuchs' endothelial corneal dystrophy (FECD) comprising:
- (a) detecting from a first sample obtained from a presymptomatic subject:
- (i) gene expression levels of COCH and one or more of FN1, CD86, CDKN2A, HLA-DRA, CTGF, COL9A3, COL4A2, BCL2, ACKR1, CADM3, KDR, SOD3, and ANXA3;
- and
- (ii) one or more skipped exon events selected from the group consisting of MBNL1, SORBS1, INF2, NUMA1, SYNE1, and MBNL2;
- (b) administering a first treatment to the presymptomatic subject based on the gene expression levels and/or skipped exon events of (a);
- (c) detecting from a second sample obtained from the presymptomatic subject after the first treatment is administered:
- (i) gene expression levels of COCH, and one or more of FN1, CD86, CDKN2A, HLA-DRA, CTGF, COL9A3, COL4A2, BCL2, ACKR1, CADM3, KDR, SOD3, and ANXA3;
- and
- (ii) one or more skipped exon events selected from the group consisting of MBNL1, SORBS1, INF2, NUMA1, SYNE1, and MBNL2;
- (d) comparing the first sample gene expression levels and skipped exon events with the second sample gene expression levels and skipped exon events;
- and
- (e) administering a second treatment to the presymptomatic subject based on the gene expression levels and skipped exon events of (d);
- thereby monitoring treatment of FECD.
A method of monitoring progression of Fuchs' endothelial corneal dystrophy (FECD) comprising:
- (a) detecting from a first sample obtained from a presymptomatic subject:
- (i) gene expression levels of COCH and one or more of FN1, CD86, CDKN2A, HLA-DRA, CTGF, COL9A3, COL4A2, BCL2, ACKR1, CADM3, KDR, SOD3, and ANXA3;
- and
- (ii) one or more skipped exon events selected from the group consisting of MBNL1, SORBS1, INF2, NUMA1, SYNE1, and MBNL2;
- (b) detecting from a second sample obtained from the presymptomatic subject after a first treatment is administered:
- (i) gene expression levels of COCH, and one or more of FN1, CD86, CDKN2A, HLA-DRA, CTGF, COL9A3, COL4A2, BCL2, ACKRI, CADM3, KDR, SOD3, and ANXA3;
- and
- (ii) one or more skipped exon events selected from the group consisting of MBNL1, SORBS1, INF2, NUMA1, SYNE1, and MBNL2;
- (c) comparing the first sample gene expression levels and skipped exon events with the second sample gene expression levels and skipped exon events;
- and
- thereby monitoring the progression of FECD.
Dependencies are inferred from the claim text.